163 related articles for article (PubMed ID: 31164515)
1. [A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Kuwayama N; Natsume T; Kainuma O; Maruyama T; Tanaka H; Miyazaki A; Sato Y; Note H; Yoshioka T; Matsumoto Y; Suzuki K; Kato M; Oshima S; Ishigaki A; Mizumoto H; Shimizu S
Gan To Kagaku Ryoho; 2019 Apr; 46(4):721-724. PubMed ID: 31164515
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy].
Fujimoto T; Ueno T; Sakamoto K; Matsukuma S; Matsui H; Shindo Y; Tokumitsu Y; Kanekiyo S; Iida M; Tokuhisa Y; Suzuki N; Takeda S; Yoshino S; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1978-1981. PubMed ID: 28133195
[TBL] [Abstract][Full Text] [Related]
3. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y
Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Unresectable Locally Advanced Pancreatic Cancer Resulted in R0 Surgery after Chemotherapy].
Sasaki Y; Katayama H; Hosoda Y; Komoto I; Sugimoto T; Yanagihara K; Katsushima U; Kawai J; Kiyochi H; Nishiyama K; Okabe A; Oshima Y; Tsunekawa S; Ogura N; Taki Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1859-1861. PubMed ID: 29394800
[TBL] [Abstract][Full Text] [Related]
5. [Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Nakamoto S; Nishiyama R; Kaneda T; Yokota M; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Yamauchi H; Okuwaki K; Iwai T; Imaizumi H; Suzuki E; Hara A; Ichinoe M; Kida M; Watanabe M
Gan To Kagaku Ryoho; 2017 Feb; 44(2):173-176. PubMed ID: 28223678
[TBL] [Abstract][Full Text] [Related]
6. GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Yoshii H; Izumi H; Abe R; Tajiri T; Mukai M; Nomura E; Makuuchi H
Tokai J Exp Clin Med; 2019 Dec; 44(4):85-89. PubMed ID: 31768996
[TBL] [Abstract][Full Text] [Related]
7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant
Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
11. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T
Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510
[TBL] [Abstract][Full Text] [Related]
12. Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Vicente E; Quijano Y; Ielpo B; Duran H
Surg Oncol; 2017 Sep; 26(3):276-277. PubMed ID: 29804945
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.
Ohata K; Fujii H; Sadaka S; Kato-Hayashi H; Iihara H; Kobayashi R; Uemura S; Iwashita T; Shimizu M; Suzuki A
Anticancer Res; 2021 Jul; 41(7):3643-3648. PubMed ID: 34230162
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Petrillo A; Pappalardo A; Pompella L; Tirino G; Calabrese F; Laterza MM; Caterino M; Ventriglia A; Orditura M; Conzo G; Molino C; Ciardiello F; Biglietto M; De Vita F
Med Oncol; 2019 Aug; 36(10):83. PubMed ID: 31444639
[TBL] [Abstract][Full Text] [Related]
15. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer.
Kawaida H; Kono H; Amemiya H; Saitou R; Yamamoto A; Hosomura N; Watanabe M; Kimura A; Furuya S; Shimizu H; Akaike H; Kawaguchi Y; Sudo M; Itakura J; Hayakawa H; Shindo H; Takahashi EI; Takano S; Fukasawa M; Ichikawa S; Fujii H; Ichikawa D
Anticancer Res; 2018 Nov; 38(11):6537-6542. PubMed ID: 30396983
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
[TBL] [Abstract][Full Text] [Related]
18. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Gulhati P; Prakash L; Katz MHG; Wang X; Javle M; Shroff R; Fogelman D; Lee JE; Tzeng CD; Lee JH; Weston B; Tamm E; Bhosale P; Koay EJ; Maitra A; Wang H; Wolff RA; Varadhachary GR
Ann Surg Oncol; 2019 Feb; 26(2):619-627. PubMed ID: 30324485
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K
Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
